Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rauch

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.
Clinical Lung Cancer|May 29, 2012
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)Martin Früh, Richard Cathomas, Marco Siano, et al.
Pediatrics|July 31, 2020
Developing Content for Pediatric Hospital Medicine Certification Examination Using Practice AnalysisVineeta Mittal, Neha Shah, Andrew C Dwyer, et al.
Cancer Reports (Hoboken, N.J.)|June 1, 2026
Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated DisordersKandice Roberts, Paula Valiño Ramos, Saurabh Jindal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN studySacha I Rothschild, Daniel Betticher, Reinhard Zenhäusern, et al.
The Prostate|July 27, 2016
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)Richard Cathomas, Simon J Crabb, Michael Mark, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)Francesco Zappa, Cornelia Droege, Daniel Betticher, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2017
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Dieter Koeberle, Sabina Schacher, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.
Clinical Lung Cancer|May 29, 2012
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)Martin Früh, Richard Cathomas, Marco Siano, et al.
Pediatrics|July 31, 2020
Developing Content for Pediatric Hospital Medicine Certification Examination Using Practice AnalysisVineeta Mittal, Neha Shah, Andrew C Dwyer, et al.
Cancer Reports (Hoboken, N.J.)|June 1, 2026
Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated DisordersKandice Roberts, Paula Valiño Ramos, Saurabh Jindal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN studySacha I Rothschild, Daniel Betticher, Reinhard Zenhäusern, et al.
The Prostate|July 27, 2016
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)Richard Cathomas, Simon J Crabb, Michael Mark, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)Francesco Zappa, Cornelia Droege, Daniel Betticher, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2017
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Dieter Koeberle, Sabina Schacher, et al.
Pageof 6